Paul Bisaro
Director · Keenova Therapeutics plc
- 2025
- Jul 18, 2026
- 11
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Paul Bisaro files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Kristin C. Peck - $2.54M in ZTS purchases and sales in the last 12 months
- Frank A. Damelio - $501K in ZTS purchases and sales in the last 12 months
- S. Louise Phanstiel - $495K in MYGN purchases and sales in the last 12 months
- Michael B. McCallister - $233K in ZTS purchases and sales in the last 12 months
- Samraat S. Raha - $200K in MYGN purchases and sales in the last 12 months
- Rashmi Kumar - $67K in MYGN purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Paul Bisaro?
Paul Bisaro is a corporate insider, tracked as Director of MYRIAD GENETICS INC (MYGN). InsiderAlpha holds 11 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Paul Bisaro last file a Form 4?
The most recent primary Form 4 on record is dated 18 July 2026, one of 11 filings going back to 2025.
Has Paul Bisaro been buying or selling stock?
Recorded transactions: 2 open-market purchases ($179K) and 0 open-market sales across all tracked filings.
